Patient not adequately controlled with insulin therapy and hospitalized for congestive heart failure
Abstract
The data provided by cardiovascular safety studies of type 2 sodium-glucose transporter inhibitors have aroused great interest among diabetologists and other specialists. They demonstrated that these drugs reduce significantly, compared to placebo, the risk of major cardiovascular events, all cause and cardiovascular mortality, and hospitalization for heart failure in patients with type 2 diabetes at high cardiovascular risk. We report the case of a cardiovascular diabetic patient not adequately controlled by high-dose multi-injective insulin therapy and hospitalized for congestive heart failure, treated with empagliflozin in association with high doses of loop diuretic (furosemide) and sacubitril/valsartan (Diabetology).
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.